CN113786471A - 一种治疗心脏疼痛的中药组合物 - Google Patents
一种治疗心脏疼痛的中药组合物 Download PDFInfo
- Publication number
- CN113786471A CN113786471A CN202111059034.4A CN202111059034A CN113786471A CN 113786471 A CN113786471 A CN 113786471A CN 202111059034 A CN202111059034 A CN 202111059034A CN 113786471 A CN113786471 A CN 113786471A
- Authority
- CN
- China
- Prior art keywords
- parts
- traditional chinese
- chinese medicine
- medicine composition
- pain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003814 drug Substances 0.000 title claims abstract description 66
- 239000000203 mixture Substances 0.000 title claims abstract description 54
- 206010002383 Angina Pectoris Diseases 0.000 title claims abstract description 26
- 208000002193 Pain Diseases 0.000 claims abstract description 23
- 241000218176 Corydalis Species 0.000 claims abstract description 16
- 235000006886 Zingiber officinale Nutrition 0.000 claims abstract description 16
- 208000029078 coronary artery disease Diseases 0.000 claims abstract description 16
- 235000008397 ginger Nutrition 0.000 claims abstract description 16
- 244000020518 Carthamus tinctorius Species 0.000 claims abstract description 14
- 235000003255 Carthamus tinctorius Nutrition 0.000 claims abstract description 14
- 241000304531 Allium macrostemon Species 0.000 claims abstract description 13
- 244000144730 Amygdalus persica Species 0.000 claims abstract description 13
- 244000303040 Glycyrrhiza glabra Species 0.000 claims abstract description 13
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 claims abstract description 13
- 235000017443 Hedysarum boreale Nutrition 0.000 claims abstract description 13
- 235000007858 Hedysarum occidentale Nutrition 0.000 claims abstract description 13
- 244000170916 Paeonia officinalis Species 0.000 claims abstract description 13
- 235000006484 Paeonia officinalis Nutrition 0.000 claims abstract description 13
- 235000002789 Panax ginseng Nutrition 0.000 claims abstract description 13
- 241001619461 Poria <basidiomycete fungus> Species 0.000 claims abstract description 13
- 235000006040 Prunus persica var persica Nutrition 0.000 claims abstract description 13
- 240000006079 Schisandra chinensis Species 0.000 claims abstract description 13
- 239000001947 glycyrrhiza glabra rhizome/root Substances 0.000 claims abstract description 13
- 241000382455 Angelica sinensis Species 0.000 claims abstract description 12
- 235000011135 Salvia miltiorrhiza Nutrition 0.000 claims abstract description 12
- 206010008479 Chest Pain Diseases 0.000 claims abstract description 11
- 241000037740 Coptis chinensis Species 0.000 claims abstract description 10
- 241000112528 Ligusticum striatum Species 0.000 claims abstract description 10
- 235000008422 Schisandra chinensis Nutrition 0.000 claims abstract description 10
- 208000023482 precordial pain Diseases 0.000 claims abstract description 10
- 239000002994 raw material Substances 0.000 claims abstract description 8
- 244000273928 Zingiber officinale Species 0.000 claims abstract description 6
- 241001522232 Pinellia ternata Species 0.000 claims abstract description 4
- 244000132619 red sage Species 0.000 claims description 14
- 241001522129 Pinellia Species 0.000 claims description 10
- 238000000227 grinding Methods 0.000 claims description 10
- 239000000463 material Substances 0.000 claims description 10
- 238000002156 mixing Methods 0.000 claims description 10
- 230000003213 activating effect Effects 0.000 claims description 7
- 238000000034 method Methods 0.000 claims description 7
- 239000002674 ointment Substances 0.000 claims description 7
- 108010010803 Gelatin Proteins 0.000 claims description 6
- 239000008280 blood Substances 0.000 claims description 6
- 210000004369 blood Anatomy 0.000 claims description 6
- 230000017531 blood circulation Effects 0.000 claims description 6
- 230000007812 deficiency Effects 0.000 claims description 6
- 235000013399 edible fruits Nutrition 0.000 claims description 6
- 229920000159 gelatin Polymers 0.000 claims description 6
- 239000008273 gelatin Substances 0.000 claims description 6
- 235000019322 gelatine Nutrition 0.000 claims description 6
- 235000011852 gelatine desserts Nutrition 0.000 claims description 6
- 238000010792 warming Methods 0.000 claims description 6
- 238000004140 cleaning Methods 0.000 claims description 5
- 239000000084 colloidal system Substances 0.000 claims description 5
- 238000001035 drying Methods 0.000 claims description 5
- 230000001737 promoting effect Effects 0.000 claims description 5
- 238000012216 screening Methods 0.000 claims description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 5
- 108010052008 colla corii asini Proteins 0.000 claims description 4
- WTPPRJKFRFIQKT-UHFFFAOYSA-N 1,6-dimethyl-8,9-dihydronaphtho[1,2-g][1]benzofuran-10,11-dione;1-methyl-6-methylidene-8,9-dihydro-7h-naphtho[1,2-g][1]benzofuran-10,11-dione Chemical compound O=C1C(=O)C2=C3CCCC(=C)C3=CC=C2C2=C1C(C)=CO2.O=C1C(=O)C2=C3CCC=C(C)C3=CC=C2C2=C1C(C)=CO2 WTPPRJKFRFIQKT-UHFFFAOYSA-N 0.000 claims description 3
- 241000099774 Cuscuta salina Species 0.000 claims description 3
- 241000212322 Levisticum officinale Species 0.000 claims description 3
- 240000002948 Ophiopogon intermedius Species 0.000 claims description 3
- 235000008326 Trichosanthes anguina Nutrition 0.000 claims description 3
- 244000078912 Trichosanthes cucumerina Species 0.000 claims description 3
- 239000001645 levisticum officinale Substances 0.000 claims description 3
- 235000012907 honey Nutrition 0.000 claims description 2
- 235000010603 pastilles Nutrition 0.000 claims 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 22
- 238000011282 treatment Methods 0.000 abstract description 11
- 208000024891 symptom Diseases 0.000 abstract description 9
- 230000000202 analgesic effect Effects 0.000 abstract description 4
- 238000002360 preparation method Methods 0.000 abstract description 4
- 230000004044 response Effects 0.000 abstract description 4
- 230000007774 longterm Effects 0.000 abstract description 3
- 241000304195 Salvia miltiorrhiza Species 0.000 abstract 1
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 24
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 15
- 229960002748 norepinephrine Drugs 0.000 description 15
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 15
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 14
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 12
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 11
- 229960004373 acetylcholine Drugs 0.000 description 11
- 229940076279 serotonin Drugs 0.000 description 11
- UCTWMZQNUQWSLP-VIFPVBQESA-N (R)-adrenaline Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 description 10
- 229930182837 (R)-adrenaline Natural products 0.000 description 10
- 241000234314 Zingiber Species 0.000 description 10
- 229960005139 epinephrine Drugs 0.000 description 10
- 239000002671 adjuvant Substances 0.000 description 9
- 229940079593 drug Drugs 0.000 description 9
- 229930195712 glutamate Natural products 0.000 description 9
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 8
- 230000002401 inhibitory effect Effects 0.000 description 8
- 239000007937 lozenge Substances 0.000 description 8
- 229960001340 histamine Drugs 0.000 description 6
- 230000004060 metabolic process Effects 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 5
- OGNSCSPNOLGXSM-UHFFFAOYSA-N (+/-)-DABA Natural products NCCC(N)C(O)=O OGNSCSPNOLGXSM-UHFFFAOYSA-N 0.000 description 4
- 229940100578 Acetylcholinesterase inhibitor Drugs 0.000 description 4
- 239000000544 cholinesterase inhibitor Substances 0.000 description 4
- 235000021551 crystal sugar Nutrition 0.000 description 4
- 229960003692 gamma aminobutyric acid Drugs 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- 241000721047 Danaus plexippus Species 0.000 description 3
- 206010061218 Inflammation Diseases 0.000 description 3
- 102000010909 Monoamine Oxidase Human genes 0.000 description 3
- 108010062431 Monoamine oxidase Proteins 0.000 description 3
- 229940091512 Monoamine oxidase A inhibitor Drugs 0.000 description 3
- AIGAZQPHXLWMOJ-UHFFFAOYSA-N Tanshinone I Chemical compound C1=CC2=C(C)C=CC=C2C(C(=O)C2=O)=C1C1=C2C(C)=CO1 AIGAZQPHXLWMOJ-UHFFFAOYSA-N 0.000 description 3
- 210000004351 coronary vessel Anatomy 0.000 description 3
- 235000013922 glutamic acid Nutrition 0.000 description 3
- 239000004220 glutamic acid Substances 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 239000011265 semifinished product Substances 0.000 description 3
- 229940126680 traditional chinese medicines Drugs 0.000 description 3
- KWGRBVOPPLSCSI-WPRPVWTQSA-N (-)-ephedrine Chemical compound CN[C@@H](C)[C@H](O)C1=CC=CC=C1 KWGRBVOPPLSCSI-WPRPVWTQSA-N 0.000 description 2
- 108010022752 Acetylcholinesterase Proteins 0.000 description 2
- 102000012440 Acetylcholinesterase Human genes 0.000 description 2
- 206010001497 Agitation Diseases 0.000 description 2
- 206010010904 Convulsion Diseases 0.000 description 2
- 241000628997 Flos Species 0.000 description 2
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 2
- UILPJVPSNHJFIK-UHFFFAOYSA-N Paeonol Chemical compound COC1=CC=C(C(C)=O)C(O)=C1 UILPJVPSNHJFIK-UHFFFAOYSA-N 0.000 description 2
- 206010042434 Sudden death Diseases 0.000 description 2
- 240000006023 Trichosanthes kirilowii Species 0.000 description 2
- 235000009818 Trichosanthes kirilowii Nutrition 0.000 description 2
- 229940022698 acetylcholinesterase Drugs 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 230000000747 cardiac effect Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 230000036461 convulsion Effects 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 238000012423 maintenance Methods 0.000 description 2
- 210000005036 nerve Anatomy 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- WCGUUGGRBIKTOS-GPOJBZKASA-N (3beta)-3-hydroxyurs-12-en-28-oic acid Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CC[C@@H](C)[C@H](C)[C@H]5C4=CC[C@@H]3[C@]21C WCGUUGGRBIKTOS-GPOJBZKASA-N 0.000 description 1
- OQWKEEOHDMUXEO-UHFFFAOYSA-N (6)-shogaol Natural products CCCCCC=CC(=O)CCC1=CC=C(O)C(OC)=C1 OQWKEEOHDMUXEO-UHFFFAOYSA-N 0.000 description 1
- IQVQXVFMNOFTMU-FLIBITNWSA-N (Z)-ligustilide Chemical compound C1CC=CC2=C1C(=C/CCC)/OC2=O IQVQXVFMNOFTMU-FLIBITNWSA-N 0.000 description 1
- HARGZZNYNSYSGJ-UHFFFAOYSA-N 1,2 dihydrotanshinquinone Natural products C1=CC2=C(C)C=CC=C2C(C(=O)C2=O)=C1C1=C2C(C)CO1 HARGZZNYNSYSGJ-UHFFFAOYSA-N 0.000 description 1
- 244000061520 Angelica archangelica Species 0.000 description 1
- 206010008469 Chest discomfort Diseases 0.000 description 1
- 241000218202 Coptis Species 0.000 description 1
- 235000002991 Coptis groenlandica Nutrition 0.000 description 1
- 201000000057 Coronary Stenosis Diseases 0.000 description 1
- 206010011089 Coronary artery stenosis Diseases 0.000 description 1
- GVKKJJOMQCNPGB-JTQLQIEISA-N Cryptotanshinone Chemical compound O=C1C(=O)C2=C3CCCC(C)(C)C3=CC=C2C2=C1[C@@H](C)CO2 GVKKJJOMQCNPGB-JTQLQIEISA-N 0.000 description 1
- GVKKJJOMQCNPGB-UHFFFAOYSA-N Cryptotanshinone Natural products O=C1C(=O)C2=C3CCCC(C)(C)C3=CC=C2C2=C1C(C)CO2 GVKKJJOMQCNPGB-UHFFFAOYSA-N 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 240000001879 Digitalis lutea Species 0.000 description 1
- HARGZZNYNSYSGJ-JTQLQIEISA-N Dihydrotanshinone I Chemical compound C1=CC2=C(C)C=CC=C2C(C(=O)C2=O)=C1C1=C2[C@@H](C)CO1 HARGZZNYNSYSGJ-JTQLQIEISA-N 0.000 description 1
- 235000001287 Guettarda speciosa Nutrition 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- QELDJEKNFOQJOY-ZDUSSCGKSA-N Isocorydine Chemical compound CN1CCC2=CC(OC)=C(OC)C3=C2[C@@H]1CC1=CC=C(OC)C(O)=C13 QELDJEKNFOQJOY-ZDUSSCGKSA-N 0.000 description 1
- SNIOPGDIGTZGOP-UHFFFAOYSA-N Nitroglycerin Chemical compound [O-][N+](=O)OCC(O[N+]([O-])=O)CO[N+]([O-])=O SNIOPGDIGTZGOP-UHFFFAOYSA-N 0.000 description 1
- 239000000006 Nitroglycerin Substances 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 229930194268 Salvianic acid Natural products 0.000 description 1
- PAFLSMZLRSPALU-UHFFFAOYSA-N Salvianic acid A Natural products OC(=O)C(O)CC1=CC=C(O)C(O)=C1 PAFLSMZLRSPALU-UHFFFAOYSA-N 0.000 description 1
- 206010049418 Sudden Cardiac Death Diseases 0.000 description 1
- HYXITZLLTYIPOF-UHFFFAOYSA-N Tanshinone II Natural products O=C1C(=O)C2=C3CCCC(C)(C)C3=CC=C2C2=C1C(C)=CO2 HYXITZLLTYIPOF-UHFFFAOYSA-N 0.000 description 1
- IQVQXVFMNOFTMU-DHZHZOJOSA-N Z-ligustilide Natural products C1CC=CC2=C1C(=C/CCC)\OC2=O IQVQXVFMNOFTMU-DHZHZOJOSA-N 0.000 description 1
- OQWKEEOHDMUXEO-BQYQJAHWSA-N [6]-Shogaol Chemical compound CCCCC\C=C\C(=O)CCC1=CC=C(O)C(OC)=C1 OQWKEEOHDMUXEO-BQYQJAHWSA-N 0.000 description 1
- 230000001800 adrenalinergic effect Effects 0.000 description 1
- 239000000674 adrenergic antagonist Substances 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- YBHILYKTIRIUTE-UHFFFAOYSA-N berberine Chemical compound C1=C2CC[N+]3=CC4=C(OC)C(OC)=CC=C4C=C3C2=CC2=C1OCO2 YBHILYKTIRIUTE-UHFFFAOYSA-N 0.000 description 1
- 229940093265 berberine Drugs 0.000 description 1
- QISXPYZVZJBNDM-UHFFFAOYSA-N berberine Natural products COc1ccc2C=C3N(Cc2c1OC)C=Cc4cc5OCOc5cc34 QISXPYZVZJBNDM-UHFFFAOYSA-N 0.000 description 1
- 102000012740 beta Adrenergic Receptors Human genes 0.000 description 1
- 108010079452 beta Adrenergic Receptors Proteins 0.000 description 1
- 230000004856 capillary permeability Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000002586 coronary angiography Methods 0.000 description 1
- KWGRBVOPPLSCSI-UHFFFAOYSA-N d-ephedrine Natural products CNC(C)C(O)C1=CC=CC=C1 KWGRBVOPPLSCSI-UHFFFAOYSA-N 0.000 description 1
- 239000009524 danshen dripping Substances 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- XEYBRNLFEZDVAW-ARSRFYASSA-N dinoprostone Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O XEYBRNLFEZDVAW-ARSRFYASSA-N 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 230000008451 emotion Effects 0.000 description 1
- 229960002179 ephedrine Drugs 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 229960003711 glyceryl trinitrate Drugs 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- YLTGFGDODHXMFB-UHFFFAOYSA-N isoacetovanillon Natural products COC1=CC=C(C(C)=O)C=C1O YLTGFGDODHXMFB-UHFFFAOYSA-N 0.000 description 1
- DRVVGOFZCWCCSA-UHFFFAOYSA-N isocorydine Natural products COc1cc2CCN(C)C3Cc4cccc(C)c4c(c1O)c23 DRVVGOFZCWCCSA-UHFFFAOYSA-N 0.000 description 1
- 239000009335 naoxintong Substances 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- MLIBGOFSXXWRIY-UHFFFAOYSA-N paeonol Natural products COC1=CC=C(O)C(C(C)=O)=C1 MLIBGOFSXXWRIY-UHFFFAOYSA-N 0.000 description 1
- 235000017807 phytochemicals Nutrition 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 229930000223 plant secondary metabolite Natural products 0.000 description 1
- 230000000770 proinflammatory effect Effects 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- KINGXFAMZNIVNL-SXQDSXCISA-N safflor yellow A Natural products OC[C@@H]1O[C@H]2[C@H](OC3=C2C(=O)C(=C(O)C=Cc4ccc(O)cc4)C(=O)[C@]3(O)[C@@H]5O[C@H](CO)[C@@H](O)[C@H](O)[C@H]5O)[C@@H](O)[C@H]1O KINGXFAMZNIVNL-SXQDSXCISA-N 0.000 description 1
- AZEZEAABTDXEHR-UHFFFAOYSA-M sodium;1,6,6-trimethyl-10,11-dioxo-8,9-dihydro-7h-naphtho[1,2-g][1]benzofuran-2-sulfonate Chemical compound [Na+].C12=CC=C(C(CCC3)(C)C)C3=C2C(=O)C(=O)C2=C1OC(S([O-])(=O)=O)=C2C AZEZEAABTDXEHR-UHFFFAOYSA-M 0.000 description 1
- 208000014221 sudden cardiac arrest Diseases 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 229940096998 ursolic acid Drugs 0.000 description 1
- PLSAJKYPRJGMHO-UHFFFAOYSA-N ursolic acid Natural products CC1CCC2(CCC3(C)C(C=CC4C5(C)CCC(O)C(C)(C)C5CCC34C)C2C1C)C(=O)O PLSAJKYPRJGMHO-UHFFFAOYSA-N 0.000 description 1
- MWOOGOJBHIARFG-UHFFFAOYSA-N vanillin Chemical compound COC1=CC(C=O)=CC=C1O MWOOGOJBHIARFG-UHFFFAOYSA-N 0.000 description 1
- FGQOOHJZONJGDT-UHFFFAOYSA-N vanillin Natural products COC1=CC(O)=CC(C=O)=C1 FGQOOHJZONJGDT-UHFFFAOYSA-N 0.000 description 1
- 235000012141 vanillin Nutrition 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 229940126673 western medicines Drugs 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/236—Ligusticum (licorice-root)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/07—Basidiomycota, e.g. Cryptococcus
- A61K36/076—Poria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/232—Angelica
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
- A61K36/258—Panax (ginseng)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/286—Carthamus (distaff thistle)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/42—Cucurbitaceae (Cucumber family)
- A61K36/428—Trichosanthes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/484—Glycyrrhiza (licorice)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/537—Salvia (sage)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/57—Magnoliaceae (Magnolia family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/65—Paeoniaceae (Peony family), e.g. Chinese peony
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/66—Papaveraceae (Poppy family), e.g. bloodroot
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/71—Ranunculaceae (Buttercup family), e.g. larkspur, hepatica, hydrastis, columbine or goldenseal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/71—Ranunculaceae (Buttercup family), e.g. larkspur, hepatica, hydrastis, columbine or goldenseal
- A61K36/718—Coptis (goldthread)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
- A61K36/736—Prunus, e.g. plum, cherry, peach, apricot or almond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/79—Schisandraceae (Schisandra family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/888—Araceae (Arum family), e.g. caladium, calla lily or skunk cabbage
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/888—Araceae (Arum family), e.g. caladium, calla lily or skunk cabbage
- A61K36/8888—Pinellia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
- A61K36/8962—Allium, e.g. garden onion, leek, garlic or chives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
- A61K36/8968—Ophiopogon (Lilyturf)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/906—Zingiberaceae (Ginger family)
- A61K36/9068—Zingiber, e.g. garden ginger
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation or decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Mycology (AREA)
- Botany (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
本发明提供一种治疗心脏疼痛的中药组合物，由下述重量配比的原料制成：川芎280～305份、当归260～310份、丹参290～330份、赤芍260～308份、桃仁180～190份、红花165～180份、红参135～150份、麦冬280～305份、五味子290～305份、炙甘草290～305份、石菖蒲260～310份、云苓260～310份、半夏290～305份、生姜170～185份、黄连135～150份、全瓜蒌290～330份、薤白290～330份、元胡225～245份。本发明是为了解决目前市场上缺乏起效快并能保持长期疗效的冠心病疼痛治疗药物的问题，采用中药锭制剂方法，病人携带方便，服用方便，药物有效成分能够有效保全。本发明治疗冠心病心痛症状，见效快，长期缓解，治疗一段时间后停药还会维持数年。平均止痛时间为为一到三天，所有年龄段均显示出明显疗效。不仅对普通心痛病人有即时效果，而且对冠脉支架术后胸前区疼痛有良效。
Description
技术领域
本发明涉及医学技术领域，具体涉及一种治疗心脏疼痛的中药组合物。
背景技术
目前市场上治疗冠心病疼痛的方式有四类：第一，西药，例如硝酸甘油等，这类药主要的原理是阔张冠脉为主，见效快维持时间短。第二，中药快速制剂，例如速效救心丸、丹参滴丸等，这类药也是见效快维持时间短。第三，中药慢作用制剂，例如步长脑心通类，这类药见效时间慢，单用很难短时间有明显疗效。第四，冠脉手术，例如支架和搭桥等，这个方法，有的患者即使做了支架和搭桥手术，还是会疼痛。
发明内容
本发明是为了解决目前市场上缺乏起效快并能保持长期疗效的冠心病疼痛治疗药物及方法的问题，采用中药锭的制剂方法，病人携带方便，服用方便，药物有效成分能够有效保全。本药方针对治疗冠心病心痛症状，见效快，长期缓解，治疗一段时间后停药还会维持数年。平均止痛时间为为一到三天，所有年龄段均显示出明显疗效。不仅对普通心痛病人有即时效果，而且对冠脉支架术后胸前区疼痛有良效。
本发明提供一种治疗心脏疼痛的中药组合物，由下述重量配比的原料制成：川芎280～305份、当归260～310份、丹参290～330份、赤芍260～308份、桃仁180～190份、红花165～180份、红参135～150份、麦冬280～305份、五味子290～305份、炙甘草290～305份、石菖蒲260～310份、云苓260～310份、半夏290～305份、生姜170～185份、黄连135～150份、全瓜蒌290～330份、薤白290～330份、元胡225～245份；
中药组合物由如下方法制备而成：
(1)将川芎、当归、丹参、赤芍、桃仁、红花、红参、麦冬、五味子、炙甘草、石菖蒲、云苓、半夏、生姜、黄连、全瓜蒌、薤白和元胡进行筛选、清洗、切片，然后与水按照重量比为1:5～20混合，并在100～150摄氏度下熬制，得到一次浓缩液；
(2)将一次浓缩液放入浓缩罐中进行二段浓缩，得到二次浓缩液；
(3)将二次浓缩液与胶剂或者辅料混合后进行浓缩收膏得到药膏，将药膏进行干燥形成半成品药膏，再将半成品药膏用磨具磨成锭剂，得到锭剂中药组合物。
本发明提供一种治疗心脏疼痛的中药组合物，作为优选方式，各中药原料的重量配比是：川芎300份、当归300份、丹参300份、赤芍300份、桃仁180份、红花180份、红参150份、麦冬300份、五味子300份、炙甘草300份、石菖蒲300份、云苓300份、半夏300份、生姜180份、黄连150份、全瓜蒌300份、薤白300份、元胡240份。
本发明提供一种治疗心脏疼痛的中药组合物，作为优选方式，胶剂为阿胶。
本发明提供一种治疗心脏疼痛的中药组合物，作为优选方式，辅料为冰糖或蜂蜜。
本发明提供一种治疗心脏疼痛的中药组合物，作为优选方式，中药组合物用于治疗冠心病疼痛。
本发明提供一种治疗心脏疼痛的中药组合物，作为优选方式，中药组合物用于治疗冠脉支架术后的患者的胸前区疼痛。
本发明提供一种治疗心脏疼痛的中药组合物，作为优选方式，中药组合物用于活血祛瘀、通阳补虚、温经止痛。
本发明提供一种治疗心脏疼痛的中药组合物，作为优选方式，中药组合物根据能态转换理论进行配制。
本发明参考的技术文献包括：第一，医学能态转换理论数据库；第二，中药原植物化学成分集(2009年科学出版社出版的图书，作者是周家驹，谢桂荣，严新建)。
本发明活血祛瘀、通阳补虚、温经止痛。
瓜蒌、元胡，抑制去甲肾上腺素分泌，降低去甲肾上腺素风暴风险，减少猝死风险，为君。
丹参增加乙酰胆碱酯酶、单胺氧化酶水平，提高心脏神经张力，抑制炎症，为臣。
生姜降低组胺水平，降低五羟色胺水平，降低去甲肾上腺素水平，具有抗炎、止痛作用，为佐。
黄连、半夏增加去甲肾上腺素水平，为使。川芎、赤芍、红花、当归、丹参，抑制心内谷氨酸水平，抗惊厥、止痛。
心属少阴，治疗从本从标。
本发明的原理如下：
如上表及图1、图2所示，此组方中使生命活性物质谷氨酸(Glu)减少的化学成分为8种，使生命活性物质伽马氨基丁酸(GABA)增加的化学成分为1种，使生命活性物质乙酰胆碱(Achs)增加的化学成分为5种，使生命活性物质肾上腺素(NA)减少的化学成分为6种、增加的化学成分为1种，使生命活性物质五羟色胺(5-HTs)增加的化学成分为4种，使生命活性物质组胺(HAs)增加的化学成分为1种。
全瓜蒌成分1048伽马氨基丁酸(GABA)，它是抑制性神经递质，可以拮抗肾上腺素(NA)，使肾上腺素下降，防治肾上腺素风暴的重要成分。
丹参成分4292隐丹参酮，它是单胺氧化酶A抑制剂，乙酰胆碱酯酶抑制剂，它主要抑制五羟色胺(5-HTs)代谢和乙酰胆碱(Achs)代谢，它增加了体内五羟色胺和乙酰胆碱的含量。乙酰胆碱系统抑制组胺系统，抑制炎症因子风暴。五羟色胺具有防治乙酰胆碱过渡增加引起的去甲肾上腺素增加。
元胡成分11344异紫堇定，它是肾上腺素拮抗剂，直接抑制肾上腺素风暴。
丹参成分5722，二氢丹参酮I，它是单胺氧化酶A抑制剂，乙酰胆碱酯酶抑制剂，它主要抑制五羟色胺代谢(5-HTs)和乙酰胆碱代谢，它增加了体内五羟色胺和乙酰胆碱的含量
丹参成分20685丹参酮I是单胺氧化酶A抑制剂也是乙酰胆碱酯酶抑制剂，它主要抑制五羟色胺代谢(5-HTs)和乙酰胆碱代谢，它增加了体内五羟色胺和乙酰胆碱的含量。
丹参成分20686(丹参酮IIa)是乙酰胆碱酯酶抑制剂，它抑制乙酰胆碱的代谢，增加了乙酰胆碱的含量。
生姜成分19846姜烯酚，降低体内组胺(HAs)含量，组胺是引起过敏和炎症的主要因素。它还能抑制去甲肾上腺素。
黄连成分2303小檗碱，它是去甲肾上腺素α1、α2受体激动剂，增加去甲肾上腺素α1、α2的兴奋性，它可以抑制肾上腺素β受体，可抑制肾上腺素增加引起的肾上腺素风暴。
半夏成分6815麻黄碱，增加去甲肾上腺素α、β兴奋性，意味着它增加去甲肾上腺素(肾上腺素)含量。避免肾上腺素(去甲肾上腺素)下降过快引起心脏骤停。可以抑制单胺氧化酶A引起的五羟色胺(5-HT)增加。
川芎成分15370新川芎内酯，抑制谷氨酸(Glu)释放。
赤芍成分16532丹皮酚，抑制电流引起的谷氨酸下降；抑制原炎症细胞因子，抑制谷氨酸释放；抑制一氧化氮NO、前列腺素E2(PGE2)，抑制谷氨酸递质释放。
红花成分19111红花黄色素，抑制谷氨酸递质释放；抑制组胺，通过抑制组胺，抑制毛细血管通透性，防止组织水肿。
川芎成分19737洋川芎内酯G，抑制谷氨酸递质的释放。
川芎成分19738洋川芎内酯H，抑制谷氨酸递质的释放。
丹参成分22270熊果酸，抑制谷氨酸递质释放，抑制肾上腺素释放。
川芎、当归成分22336香草醛，抑制谷氨酸递质释放。
根据药效公式,心痛立锭为冠心病治疗强效药物：
公式中E代表一个剂型的中药方剂对人体内一个病的总作用强度，a代表单位中药主要有效成分，as代表单位中药系统增效成分，Bs代表靶系统兴奋，X代表药物其他成分综合效应和饮食，气候，光，情绪等对人体内网络的影响，为变数。
根据上述公式我们在临床治疗上对君药的选择可有单体和单位中药，多味中药多种方式，用不同通路相同疗效的单多靶药物为臣或佐。用兴奋靶位的药为使，调整靶稳态。
瓜蒌、元胡，抑制去甲肾上腺素分泌，降低去甲肾上腺素风暴风险，减少猝死风险，为君。
丹参增加乙酰胆碱酯酶、单胺氧化酶水平，提高心脏神经张力，抑制炎症，为臣。生姜降低组胺水平，降低五羟色胺水平，降低去甲肾上腺素水平，具有抗炎、止痛作用，为佐。黄连、半夏增加去甲肾上腺素水平，为使。川芎、赤芍、红花、当归、丹参，抑制心内谷氨酸水平，抗惊厥、止痛。心属少阴，治疗从本从标。
本发明具有以下优点：
本发明能够快速、有效、长效的治疗冠心病疼痛病症。经过11年临床验证有效，为目前市场上鲜有的治疗冠心病疼痛病症药物。本成果能够有效治疗冠心病相关各类疼痛病症，不仅能够对普通心痛症状起到即时效果，缓解患者疼痛，而且对做过冠脉支架术后的患者的胸前区疼痛症状有优良的治疗效果。本智力成果中包含的中药均为安全可靠中药，无毒、久服不伤人。
附图说明
图1为一种治疗心脏疼痛的中药组合物原理图1；
图2为一种治疗心脏疼痛的中药组合物原理图2。
具体实施方式
下面将结合本发明实施例中的附图，对本发明实施例中的技术方案进行清楚、完整地描述，显然，所描述的实施例仅仅是本发明一部分实施例，而不是全部的实施例。
实施例1
一种治疗心脏疼痛的中药组合物，由下述重量配比的原料制成：川芎280～305份、当归260～310份、丹参290～330份、赤芍260～308份、桃仁180～190份、红花165～180份、红参135～150份、麦冬280～305份、五味子290～305份、炙甘草290～305份、石菖蒲260～310份、云苓260～310份、半夏290～305份、生姜170～185份、黄连135～150份、全瓜蒌290～330份、薤白290～330份、元胡225～245份；
中药组合物由如下方法制备而成：
(1)将川芎、当归、丹参、赤芍、桃仁、红花、红参、麦冬、五味子、炙甘草、石菖蒲、云苓、半夏、生姜、黄连、全瓜蒌、薤白和元胡进行筛选、清洗、切片，然后与水按照重量比为1:5～20混合，并在100～150摄氏度下熬制，得到一次浓缩液；
(2)将一次浓缩液放入浓缩罐中进行二段浓缩，得到二次浓缩液；
(3)将二次浓缩液与胶剂或者辅料混合后进行浓缩收膏得到药膏，将药膏进行干燥形成半成品药膏，再将半成品药膏用磨具磨成锭剂，得到锭剂中药组合物；
胶剂为阿胶，辅料为冰糖或蜂蜜；
中药组合物用于治疗冠心病疼痛，用于治疗冠脉支架术后的患者的胸前区疼痛；
中药组合物用于活血祛瘀、通阳补虚、温经止痛。
实施例2
一种治疗心脏疼痛的中药组合物，由下述重量配比的原料制成：川芎285份、当归260份、丹参320份、赤芍265份、桃仁185份、红花170份、红参140份、麦冬285份、五味子295份、炙甘草300份、石菖蒲275份、云苓275份、半夏300份、生姜175份、黄连140份、全瓜蒌320份、薤白320份、元胡230份；
中药组合物由如下方法制备而成：
(1)将川芎、当归、丹参、赤芍、桃仁、红花、红参、麦冬、五味子、炙甘草、石菖蒲、云苓、半夏、生姜、黄连、全瓜蒌、薤白和元胡进行筛选、清洗、切片，然后与水按照重量比为1:15混合，并在100～150摄氏度下熬制，得到一次浓缩液；
(2)将一次浓缩液放入浓缩罐中进行二段浓缩，得到二次浓缩液；
(3)将二次浓缩液与胶剂或者辅料混合后进行浓缩收膏得到药膏，将药膏进行干燥形成半成品药膏，再将半成品药膏用磨具磨成锭剂，得到锭剂中药组合物；
胶剂为阿胶，辅料为冰糖或蜂蜜；
中药组合物用于治疗冠心病疼痛，用于治疗冠脉支架术后的患者的胸前区疼痛；
中药组合物用于活血祛瘀、通阳补虚、温经止痛。
实施例3
一种治疗心脏疼痛的中药组合物，由下述重量配比的原料制成：川芎300份、当归300份、丹参300份、赤芍300份、桃仁180份、红花180份、红参150份、麦冬300份、五味子300份、炙甘草300份、石菖蒲300份、云苓300份、半夏300份、生姜180份、黄连150份、全瓜蒌300份、薤白300份、元胡240份；；
中药组合物由如下方法制备而成：
(1)将川芎、当归、丹参、赤芍、桃仁、红花、红参、麦冬、五味子、炙甘草、石菖蒲、云苓、半夏、生姜、黄连、全瓜蒌、薤白和元胡进行筛选、清洗、切片，然后与水按照重量比为1:10混合，并在100～150摄氏度下熬制，得到一次浓缩液；
(2)将一次浓缩液放入浓缩罐中进行二段浓缩，得到二次浓缩液；
(3)将二次浓缩液与胶剂或者辅料混合后进行浓缩收膏得到药膏，将药膏进行干燥形成半成品药膏，再将半成品药膏用磨具磨成锭剂，得到锭剂中药组合物；
胶剂为阿胶，辅料为冰糖或蜂蜜；
中药组合物用于治疗冠心病疼痛，用于治疗冠脉支架术后的患者的胸前区疼痛；
中药组合物用于活血祛瘀、通阳补虚、温经止痛。
我们回顾性总结了2010年至2020年十一年间治疗冠心病心痛患者门诊治疗数据，我们选择实施例1-3的处方治疗，取得了很强的门诊治疗效应。
我们选择的门诊处方的使用标准是患者患有以下症状：1胸痛，2胸闷，3有下列证据之一：a冠脉造影显示有冠脉50％以上狭窄，b冠脉CTA显示冠脉狭窄，c心电图显示明显ST-T改变。
如表1和表2所示，2010年到2020年11月，十一年间开出的治疗冠心病心痛门诊处方共786张，其中，男性260人张，女性526人张。30-49岁116人张，其中男性35人张，女性81人张；50-60岁100人张，其中男性36人张，女性64人张。60-70岁96人张，其中男性36人张，女性60人张；70岁以上100人张，其中男39人张，女性61人张；其他(年龄登记不祥)共计374人张，其中男114张，女260人张。
表1 2010年-2020年男性患者年龄分布表
表2 2010年-2020年女性患者年龄分布表
| 女 | 10年 | 11年 | 12年 | 13年 | 14年 | 15年 | 16年 | 17年 | 18年 | 19年 | 20年 | 合计 |
| 30-49 | 2 | 3 | 3 | 14 | 5 | 2 | 4 | 21 | 4 | 17 | 6 | 81 |
| 50-60 | 5 | 1 | 1 | 2 | 2 | 3 | 5 | 1 | 13 | 15 | 16 | 64 |
| 60-70 | 2 | 2 | 1 | 3 | 9 | 7 | 10 | 2 | 7 | 7 | 10 | 60 |
| 70以上 | 3 | 1 | 3 | 1 | 6 | 10 | 8 | 5 | 4 | 10 | 10 | 61 |
| 其他 | 14 | 29 | 29 | 29 | 35 | 33 | 28 | 30 | 16 | 15 | 2 | 260 |
| 合计 | 26 | 36 | 37 | 49 | 57 | 55 | 55 | 59 | 44 | 64 | 44 | 526 |
具有前述诊断特征的患者门诊评价均以患者止痛时间和复发率为判断标准，平均止痛时间为1到3天，所有年龄段均显示出明显疗效，门诊脱靶率为30％，复诊患者均可得到有效回访，有效率为70％。
上述处方不仅对普通心痛病人有即时效果，而且对冠脉支架术后胸前区疼痛有良效。
案例1：张xx男68冠脉支架术后胸前区疼痛，六天起效，一月症状消失，停药。
案例2：吴xx女70冠脉支架术后胸前区疼痛，当天起效，十五天症状消失，停药。两年后复发，服药后当日减轻，九日停药，一年后复发，再服药，当日减轻，九日停药。
以上所述，仅为本发明较佳的具体实施方式，但本发明的保护范围并不局限于此，任何熟悉本技术领域的技术人员在本发明揭露的技术范围内，根据本发明的技术方案及其发明构思加以等同替换或改变，都应涵盖在本发明的保护范围之内。
Claims (7)
1.一种治疗心脏疼痛的中药组合物，其特征在于：由下述重量配比的原料制成：川芎280～305份、当归260～310份、丹参290～330份、赤芍260～308份、桃仁180～190份、红花165～180份、红参135～150份、麦冬280～305份、五味子290～305份、炙甘草290～305份、石菖蒲260～310份、云苓260～310份、半夏290～305份、生姜170～185份、黄连135～150份、全瓜蒌290～330份、薤白290～330份、元胡225～245份；
所述中药组合物由如下方法制备而成：
(1)将川芎、当归、丹参、赤芍、桃仁、红花、红参、麦冬、五味子、炙甘草、石菖蒲、云苓、半夏、生姜、黄连、全瓜蒌、薤白和元胡进行筛选、清洗、切片，然后与水按照重量比为1:5～20混合，并在100～150摄氏度下熬制，得到一次浓缩液；
(2)将所述一次浓缩液放入浓缩罐中进行二段浓缩，得到二次浓缩液；
(3)将所述二次浓缩液与胶剂或者辅料混合后进行浓缩收膏得到药膏，将所述药膏进行干燥形成半成品药膏，再将所述半成品药膏用磨具磨成锭剂，得到锭剂中药组合物。
2.根据权利要求1所述的一种治疗心脏疼痛的中药组合物，其特征在于：各中药原料的重量配比是：川芎300份、当归300份、丹参300份、赤芍300份、桃仁180份、红花180份、红参150份、麦冬300份、五味子300份、炙甘草300份、石菖蒲300份、云苓300份、半夏300份、生姜180份、黄连150份、全瓜蒌300份、薤白300份、元胡240份。
3.根据权利要求1所述的一种治疗心脏疼痛的中药组合物，其特征在于：所述胶剂为阿胶。
4.根据权利要求1所述的一种治疗心脏疼痛的中药组合物，其特征在于：所述辅料为冰糖或蜂蜜。
5.根据权利要求1所述的一种治疗心脏疼痛的中药组合物，其特征在于：所述中药组合物用于治疗冠心病疼痛。
6.根据权利要求1所述的一种治疗心脏疼痛的中药组合物，其特征在于：所述中药组合物用于治疗冠脉支架术后的患者的胸前区疼痛。
7.根据权利要求1所述的一种治疗心脏疼痛的中药组合物，其特征在于：所述中药组合物用于活血祛瘀、通阳补虚、温经止痛。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202111059034.4A CN113786471B (zh) | 2021-09-10 | 2021-09-10 | 一种治疗心脏疼痛的中药组合物 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202111059034.4A CN113786471B (zh) | 2021-09-10 | 2021-09-10 | 一种治疗心脏疼痛的中药组合物 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN113786471A true CN113786471A (zh) | 2021-12-14 |
| CN113786471B CN113786471B (zh) | 2022-12-20 |
Family
ID=78879892
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202111059034.4A Active CN113786471B (zh) | 2021-09-10 | 2021-09-10 | 一种治疗心脏疼痛的中药组合物 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN113786471B (zh) |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1295843A (zh) * | 2000-09-14 | 2001-05-23 | 车绍文 | 一种治疗冠心病的中药及其制备方法 |
| CN1301554A (zh) * | 1999-12-24 | 2001-07-04 | 冯俭明 | 一种治疗冠心病的药物 |
| CN104138513A (zh) * | 2013-05-10 | 2014-11-12 | 哈尔滨济博生物技术开发有限公司 | 一种治疗心绞痛气血两虚型冠心病的药物 |
| CN105902793A (zh) * | 2016-05-31 | 2016-08-31 | 汤曙光 | 一种治疗冠心病的中药 |
| CN108498622A (zh) * | 2017-02-23 | 2018-09-07 | 威海康辉生物科技有限公司 | 一种治疗冠心病的中药组合物 |
| CN110680871A (zh) * | 2019-10-16 | 2020-01-14 | 时士彩 | 一种治疗冠心病的中药组合物 |
-
2021
- 2021-09-10 CN CN202111059034.4A patent/CN113786471B/zh active Active
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1301554A (zh) * | 1999-12-24 | 2001-07-04 | 冯俭明 | 一种治疗冠心病的药物 |
| CN1295843A (zh) * | 2000-09-14 | 2001-05-23 | 车绍文 | 一种治疗冠心病的中药及其制备方法 |
| CN104138513A (zh) * | 2013-05-10 | 2014-11-12 | 哈尔滨济博生物技术开发有限公司 | 一种治疗心绞痛气血两虚型冠心病的药物 |
| CN105902793A (zh) * | 2016-05-31 | 2016-08-31 | 汤曙光 | 一种治疗冠心病的中药 |
| CN108498622A (zh) * | 2017-02-23 | 2018-09-07 | 威海康辉生物科技有限公司 | 一种治疗冠心病的中药组合物 |
| CN110680871A (zh) * | 2019-10-16 | 2020-01-14 | 时士彩 | 一种治疗冠心病的中药组合物 |
Non-Patent Citations (4)
| Title |
|---|
| 刘俊杰等: "益气养阴活血法治疗冠心病52例", 《医药论坛杂志》 * |
| 李耀等: "活血通脉汤治疗心脉痹阻型心绞痛40例", 《陕西中医》 * |
| 蒋跃绒等: "陈可冀治疗心血管疾病血瘀证用药规律数据挖掘", 《中医杂志》 * |
| 陈炳焜等: "活血化瘀法在老年疾病中的临床应用体会", 《福建中医药》 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN113786471B (zh) | 2022-12-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11369654B2 (en) | Application method of Dendrobium candidum in preparing medicine for treating hypertension | |
| CN108969642B (zh) | 一种治疗慢性前列腺炎的中药复方外用制剂及其制备工艺 | |
| CN102397351A (zh) | 一种治疗失眠的中药组合物 | |
| CN113813347A (zh) | 复方紫杉醇抗肿瘤胶囊药片的制备方法及工艺 | |
| CN101757354B (zh) | 治疗痛经的药物组合物及其制备方法 | |
| CN113786471B (zh) | 一种治疗心脏疼痛的中药组合物 | |
| CN102908391A (zh) | 一种治疗皮肤病的中药组合物及其制备方法和应用 | |
| CN111375038B (zh) | 一种治疗银屑病的中药泡浴组合物、其制备方法及应用 | |
| CN114306442A (zh) | 一种治疗特应性皮炎的中药组合物及其应用 | |
| CN102552520A (zh) | 一种治疗胸痹心痛的活血止痛药物及制备工艺和应用 | |
| CN105435196A (zh) | 一种治疗气滞血瘀型冠心病心绞痛并患有慢性胃炎的外用中药药膏及其制备方法 | |
| CN114053379B (zh) | 一种降尿酸、缓解痛风的中药组合物及其制备方法和应用 | |
| WO2019142042A1 (en) | Synergistic medicinal preparation for treating skin disorders like tinea versicolor | |
| CN108186799A (zh) | 地骨五加散及制备方法 | |
| CN112675264B (zh) | 治疗银屑病的组合物、制备方法及其应用 | |
| CN112691170B (zh) | 一种治疗脱发的中药组合物及其应用 | |
| CN100435842C (zh) | 治疗高血压病的中药制剂及制备方法 | |
| CN101979073A (zh) | 一种疏肝理气药剂 | |
| CN107348508B (zh) | 一种中药保健品及其制备方法和用途 | |
| CN116077611A (zh) | 一种具有温阳益心作用的中药复方 | |
| CN116549509A (zh) | 治疗白癫风的中药组合物及其制备方法 | |
| CN118356473A (zh) | 一种治疗慢性湿疹的中药组合物及其制备方法 | |
| CN113893281A (zh) | 一种参芪降压丸及其制备方法 | |
| CN116585383A (zh) | 一种治疗排卵障碍性异常子宫出血的中药组合物及其药物制剂 | |
| CN104645245B (zh) | 一种用于女性更年期抑郁药物制剂的制备方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| TA01 | Transfer of patent application right | ||
| TA01 | Transfer of patent application right |
Effective date of registration: 20221108 Address after: 734399 The first store in the south of the gate of Dongyuan District A, Donghuan Road, Chengguan Town, Gaotai County, Zhangye City, Gansu Province Applicant after: Gansu Shengwan Biomedical Technology Co.,Ltd. Address before: 0723, floor 7, No. 26, Shangdi Information Road, Haidian District, Beijing 100085 Applicant before: Beijing shengwan Biomedical Technology Co.,Ltd. |
|
| GR01 | Patent grant | ||
| GR01 | Patent grant |